Listen to the article
Missouri’s Attorney General Expands Battle Against Generic Abortion Pills
Missouri Attorney General Catherine Hanaway announced Thursday an expansion of the state’s legal battle against mail-order abortion pills, targeting a recently FDA-approved generic version of mifepristone. Hanaway alleges the drug sends women to hospitals with “life-threatening complications” while being pushed into the marketplace without proper medical safeguards.
The lawsuit specifically challenges the Food and Drug Administration’s September 30 approval of generic mifepristone produced by Evita Solutions. According to Hanaway, the risks associated with the drug are “well-documented and worsening with further study.”
“Mifepristone is sending women to the hospital with life-threatening complications, and yet drug companies continue pushing new versions of it into the market without basic medical safeguards,” Hanaway stated. “Mail-order abortion drugs are dangerous when taken without in-person care, and Missouri will not stand by while manufacturers gamble with women’s lives.”
The legal filing contends that manufacturers have relied on “weakened safety standards” that were originally designed to identify dangerous conditions such as ectopic pregnancies—complications that can only be properly diagnosed through in-person medical examinations.
This case builds upon Missouri’s existing multi-state challenge to what officials describe as the FDA’s systematic dismantling of critical safety protections surrounding mifepristone. Missouri has joined with Kansas and Idaho in asking the court to block the new approval and restore pre-2016 safety standards that required in-person medical evaluations.
The lawsuit also seeks to stop drugmakers and distributors from mailing abortion pills nationwide, which the filing claims violates federal law. While federal regulations have long prohibited the mailing of abortion drugs, a network of distributors and telehealth services has developed a system that delivers these medications to women across all states, often without in-person screening or follow-up care.
Hanaway points to the drug’s labeling, which acknowledges that approximately one in 25 women who take chemical abortion drugs require emergency room treatment. Many suffer from hemorrhaging, infection, or need surgical intervention—complications that become more common when the pills are distributed via mail without proper medical oversight.
“No caring physician would call mifepristone ‘as safe as Tylenol,'” Hanaway said. “That claim was always false. Women are ending up in emergency rooms, and manufacturers know it. If the FDA is reevaluating the brand-name drug’s safety, then it needs to stop rubber-stamping new mail-order generic versions before more women are hurt.”
This legal action comes as Republican lawmakers in Washington continue pressing the FDA to strengthen oversight of abortion pills and reinstate safety measures that have been rolled back in recent years. During a recent press briefing, Missouri Senator Josh Hawley urged the FDA to “follow the science to put back safety guardrails” and raised questions about the agency’s relationships with abortion pill manufacturers, including Evita Solutions.
Senator Bill Cassidy of Louisiana noted that he and fellow Republican senators have demanded answers from the FDA regarding its approval of the new drug but have yet to receive a response.
The battle over abortion medication access has intensified since the Supreme Court overturned Roe v. Wade in 2022. Medication abortion, which typically involves a two-drug regimen of mifepristone followed by misoprostol, now accounts for more than half of all abortions performed in the United States, according to recent data from the Guttmacher Institute.
Advocates for reproductive rights maintain that medication abortion has been extensively studied and proven safe over more than two decades of use in the United States. They argue that restrictions on telehealth prescribing create unnecessary barriers to essential healthcare, particularly for those in rural areas or states with limited abortion access.
Evita Solutions has not yet responded to requests for comment on the lawsuit.
Fact Checker
Verify the accuracy of this article using The Disinformation Commission analysis and real-time sources.
8 Comments
The concerns around medication safety are understandable, but the broader context of reproductive rights and healthcare access should also be carefully weighed. I hope this challenge leads to a balanced, evidence-based resolution.
Agreed, it’s crucial that any regulatory actions are grounded in sound medical evidence and respect for individual rights. The stakes are high, so a measured approach is warranted.
This is a complex and sensitive issue. While safety concerns are understandable, restricting access to medical treatments could pose risks of its own. I hope regulators carefully weigh all factors to ensure women’s health and rights are protected.
Agreed, it’s a delicate balance. Reasonable safeguards are prudent, but shouldn’t unduly limit access to legitimate medical options. Careful review by experts is needed here.
Interesting development in the ongoing debate around reproductive rights and healthcare access. I’ll be curious to see how this legal challenge plays out and what the broader implications could be.
Yes, this case touches on some fundamental issues. Reasonable people can disagree, so I hope the process remains fair and evidence-based.
This seems like a complex legal and public health issue without easy answers. I’ll be following the developments closely to better understand the arguments and potential impacts on women’s healthcare.
While medication safety is paramount, restricting access to certain treatments could have unintended consequences that disproportionately impact vulnerable populations. I hope all perspectives are thoughtfully considered.